Aripiprazole Tablet
Product Images NDC 71335-1980

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 71335-1980). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A line graph showing the proportion of subjects with relapse over days from randomization for Aripiprazole and Placebo groups. The horizontal axis represents days from randomization, and the vertical axis shows the proportion with relapse. Two lines compare relapse rates over time between Aripiprazole (blue solid line) and Placebo (red dashed line). Numbers of subjects at risk are listed below the graph for each time point.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A Kaplan-Meier survival curve showing the proportion of subjects with relapse over time in days from randomization. The graph compares two groups: Aripiprazole (solid line) and Placebo (dashed line). The x-axis represents days from randomization up to 364 days, and the y-axis shows the proportion with relapse ranging from 0 to 1. Below the x-axis, the number of subjects still at risk is listed for each group at various time points.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic chart illustrating fold changes and 90% confidence intervals for dehydro-aripiprazole's AUC and Cmax when administered with various inhibitors and other drugs relative to a reference without an interacting drug. The X-axis represents the change relative to reference, ranging from 0.5 to 3.0, and the Y-axis lists drug interactions including CYP3A4 and CYP2D6 inhibitors, inducers, gastric acid blockers, and other drugs.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A chart depicting fold change and 90% confidence intervals in pharmacokinetic parameters (DMVDRP, AUC, Cmax, and INR) related to various drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The horizontal axis represents change relative to a reference condition without interacting drug, ranging from 0.5 to 3.0.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic chart illustrating the fold change of Aripiprazole and the 90% confidence intervals across various factors, including CYP2D6 metabolism status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis represents change relative to reference values, comparing AUC and Cmax parameters for each category.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A forest plot showing fold changes in dehydro-aripiprazole pharmacokinetic parameters (AUC and Cmax) with 90% confidence intervals for various factors including CYP2D6 metabolizer status, gender, age, hepatic impairment, and severe renal impairment. The horizontal axis represents the change relative to reference (1.0).*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart illustrating the fold change and 90% confidence intervals of Aripiprazole exposure (AUC and Cmax) when coadministered with various CYP3A4 and CYP2D6 inhibitors or inducers, gastric acid blockers, and other drugs. The x-axis shows change relative to reference without interacting drug, ranging from 0.0 to 3.0.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure diagram of aripiprazole, showing atomic bonds and ring formations typical of this active pharmaceutical ingredient.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier curve chart showing the proportion of subjects with relapse over 182 days from randomization, comparing Aripiprazole versus placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The chart includes the number of subjects at risk at various time points for each group.*

FDA Label Image

Label (Lbl713351980)

Aripiprazole 2 mg tablet label by Bryant Ranch Prepack, featuring comparison to Abilify 2 mg tablet by Alkem Laboratories Limited. The label includes storage instructions to keep at room temperature (20°-25°C or 68°-77°F) and a warning to keep all drugs out of reach of children. The label shows a barcode, lot number 1523487, and NDC 71335-19801.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.